Drug information of Urofollitropin
Urofollitropin is a purified form of a hormone called follicle-stimulating hormone (FSH). This hormone is important in the development of follicles (eggs) that are produced by the ovaries in women. Urofollitropin is used together with other medicines to treat infertility in women with FSH deficiency. Urofollitropin is also used to help the ovaries produce multiple eggs for use in "in-vitro" fertilization. Urofollitropin alone will not cause ovulation (production of an egg by the ovaries). You will need to receive other medicines to stimulate ovulation.
Mechanism of effect
Stimulates ovarian follicular growth in women who do not have primary ovarian failure.
Used for the treatment of female infertility, urofollitropin or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of urofollitropin is the primary hormone responsible for follicular recruitment and development.
Subcutaneous administration T max occurs in about 20 h; 17 h in IM administration. Mean elimination t ½ for subcutaneous and IM single dosing are approximately 32 and 37 h, respectively.
Drug indicationsFollicle Stimulation
Usual Adult Dose for Follicle Stimulation Ovulation induction: Initial dose: 150 international units per day for 5 days, subcutaneously (SC) or intramuscularly (IM) Maximum dose: 450 international units per day Duration of therapy: 12 days
Drug contraindicationshypersensitivity to drug or its components. , primary ovarian failure , adrenal dysfunction , abnormal uterine bleeding of undetermined origin , ovarian cysts , ovarian enlargement
Side effectsnausea , Headache , Dermatit , constipation , abdominal pain , rash , Depression , Hypertension , acne , fever , Injection-site reaction , Pain , hemorrhage , Anaphylactic reaction , Weight increase , Multiple pregnancies , mild to moderate ovarian enlargement , ovarian cysts , OHSS
1- Multiple pregnancies have occurred. 2- Mild to moderate uncomplicated ovarian enlargement may occur in approximately 20% of women treated with follitropin and hCG and generally regresses without treatment within 2 to 3 wk. 3- OHSS: Warning signs include difficulty breathing, severe pelvic pain, nausea, vomiting, rapid weight gain, stomach pain or bloating, diarrhea, or infrequent urination. Treatment must be stopped and patient hospitalized. 4- Intravascular thrombosis and embolism can reduce blood flow to critical organs (may result in pulmonary infarct) or extremities (may cause loss of limbs).
Points of recommendation
1- For subcutaneous or IM administration only when used for ovulation induction. Not for intradermal, IV, or intra-arterial administration. 2- Discard any unused solution. Do not save unused solution for later administration. 3- Store lyophilized powder in refrigerator or at room temperature (37° to 77°F). Protect from light.
Ask a Pharmacist